Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid carcinoma
We use necessary technologies to operate this website. With your permission, we also use analytics technologies
from Google Analytics and Metricool to understand how the site is used. You can accept, reject or configure
non-essential technologies at any time.
Cookie settings
Necessary
Required for core website functions and to remember your privacy choice.
Always active
Google Analytics 4 and Metricool help us understand website usage and performance.
Reserved for optional marketing or campaign technologies, such as future Mailchimp tracking.